GENETIC ANALYSIS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.64 NOK | -4.48% |
|
+18.52% | -24.71% |
| Sales 2022 | 20.75M 1.88M | Sales 2023 | 23.16M 2.1M | Capitalization | 35.83M 3.25M |
|---|---|---|---|---|---|
| Net income 2022 | -28M -2.54M | Net income 2023 | -23M -2.09M | EV / Sales 2022 | 1.71 x |
| Net cash position 2022 | 16.2M 1.47M | Net cash position 2023 | 8.87M 805K | EV / Sales 2023 | 1.16 x |
| P/E ratio 2022 |
-1.83
x | P/E ratio 2023 |
-1.37
x | Employees | 21 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 44.53% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.48% | ||
| 1 week | +18.52% | ||
| Current month | +8.47% | ||
| 1 month | +8.47% | ||
| 3 months | -11.11% | ||
| 6 months | -27.27% | ||
| Current year | -24.71% |
1 week
0.45
0.70
1 month
0.271.75
Current year
0.271.75
1 year
0.271.82
3 years
0.2713.62
5 years
0.2713.62
10 years
0.2713.62
| Managers | Title | Age | Since |
|---|---|---|---|
Ronny Hermansen
CEO | Chief Executive Officer | 62 | 14-03-31 |
Eilert Aamodt
DFI | Director of Finance/CFO | 54 | 20-12-31 |
Lars Tiller
COO | Chief Operating Officer | - | 22-03-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rune Sørum
BRD | Director/Board Member | 68 | 09-12-31 |
| Director/Board Member | 66 | 19-12-31 | |
Per Matsson
CHM | Chairman | 70 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.64 | -4.48% | 49,629 |
| 24-04-25 | 0.67 | +9.84% | 149,120 |
| 24-04-24 | 0.61 | -6.15% | 173,012 |
| 24-04-23 | 0.65 | +4.17% | 34,212 |
| 24-04-22 | 0.624 | +15.56% | 215,452 |
End-of-day quote NORDIC GROWTH MARKET, April 25, 2024
More quotes
Genetic Analysis AS is a Norway-based company active in the field of molecular diagnostics of diseases related to large and small intestine (gut) imbalances. The Company has developed a DNA-based platform technology that allows for simultaneous analysis of a number of similar (but not identical) gene fragments in one reaction. The GA-map platform technology utilizes common and variable DNA sequences within the 16S rRNA gene of the bacteria to characterize and identify the different bacteria. The technology makes it possible to generate profiles of a person's microbiota and correlate that profile to different health conditions.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.71% | 2.44M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- GEAN Stock
